Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic
Jurjen J. Luykx, Sisco van Veen, Arne Risselada, Paul Naarding, Joeri K. Tijdink, Christiaan H. Vinkers
Abstract
Treatment with psychotropic medication may sometimes be jeopardised because of the COVID-19 pandemic. One underlying reason is the lack of COVID-19-specific psychopharmacology guidelines. Here, we discuss five considerations arising from our clinical experience and pharmacological background knowledge to enable safe and well-informed psychopharmacotherapy during the COVID-19 pandemic.
Topics & Concepts
PandemicCoronavirus disease 2019 (COVID-19)2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)PsychopharmacologyMedicinePsychiatryPsychologyIntensive care medicineVirologyInfectious disease (medical specialty)DiseaseOutbreakPathologySchizophrenia research and treatmentCOVID-19 and Mental HealthAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes